CEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering

Dow Jones

07/12

By Josh Beckerman

Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering.

The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258.

The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor.

The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said.

Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow.

The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner.

Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 11, 2025 14:01 ET (18:01 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2550496379"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550496379\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550496379?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-12 02:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550496379","market":"sh","top_or_hot":-1,"title":"CEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering. \n</p>\n<p>\n  The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258. \n</p>\n<p>\n  The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor. \n</p>\n<p>\n  The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said. \n</p>\n<p>\n  Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow. \n</p>\n<p>\n  The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner. \n</p>\n<p>\n  Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 14:01 ET (18:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-12 02:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering. \n</p>\n<p>\n  The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258. \n</p>\n<p>\n  The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor. \n</p>\n<p>\n  The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said. \n</p>\n<p>\n  Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow. \n</p>\n<p>\n  The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner. \n</p>\n<p>\n  Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 14:01 ET (18:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVM","symbol_name":"CEL-SCI Corp","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550496379","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550496379","pubTimestamp":1752256860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering.The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258.The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor.The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said.Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow.Later Friday, CEL-SCI said ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CVM":"CEL-SCI Corp","BK4139":"生物科技"},"translate_title":"沙特阿拉伯药物申报更新和股票发行后CEL-SCI飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVM":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering. \n\n\n  The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258. \n\n\n  The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor. \n\n\n  The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said. \n\n\n  Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow. \n\n\n  The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner. \n\n\n  Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 11, 2025 14:01 ET (18:01 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}